Andrew Krystal

Dr. Andrew Krystal is a Professor in the Departments of Psychiatry and Neurology at the University of California, San Francisco (UCSF) School of Medicine. He serves as Vice-Chair for Research in Psychiatry, Director of the Dolby Family Center for Mood Disorders, and Co-Director of the TMS & Neuromodulation Clinic. His academic journey includes B.S.E. and M.S. degrees in Mechanical and Biomedical Engineering from M.I.T., an M.D. from Duke University, and specialized training in Psychiatry and Sleep Disorders.

Dr. Krystal's research focuses on EEG biomarker development, computational modeling, and personalized therapies for mood/sleep disorders. His work spans over 50 clinical trials, including NIH-funded studies on insomnia treatment, depression outcomes, and neuromodulation technologies like tDCS and DBS. Key areas include suicidal ideation, traumatic brain injury, and sleep pharmacogenetics.

• NIH R01DK117953: Tissue-Specific Insulin Resistance in Sleep Apnea
• NIH R21MH106772: tDCS for Acute Fear
• NIH R01MH095780: Insomnia Treatment to Reduce Suicide Risk

His recent publications highlight trends in psychiatric neurostimulation, k-opioid antagonism, and sleep disorder comorbidities. Collaborations with institutions like UCSF Weill Institute for Neurosciences and TRACK-TBI Investigators underscore his interdisciplinary impact.

Dr. Krystal's clinical and research leadership bridges sleep medicine, depression, and neurophysiological monitoring, advancing adaptive treatment strategies through large-scale trials and innovative biomarker discovery.